A drug for prevention and treatment of postpartum endometritis in cows

 

(57) Abstract:

The invention relates to veterinary medicine, in particular drugs for the prevention and treatment of diseases of the reproductive organs in the postpartum period in cows. The drug contains thelan, norsulfazol, furazolidone, licorice root extract, tansy and glycerol under the following ratios of all the original components, wt. %: thelan - 7,0 - 7,5, norsulfazol 7,0 - 7,5, furazolidone 7,0 - 7,5, licorice root 39,0 - 40,0, extract of tansy 33,0 - 35,0, glycerin - rest. The drug allows the use of suppositories, to increase the activity of the regenerative processes in the pathological tissues of the uterus, to restore reproductive function of animals.

The invention relates to veterinary medicine, in particular drugs for the prevention and treatment of diseases of the reproductive organs in the postpartum period.

In the pathology of cattle are one of the leading places is acute postpartum endometritis in cows, which in the transition to the chronic form of the flow causes they symptomatic infertility, causing farms to huge losses.

Due to the significant spread of antibiotic-resistant strains of opportunistic microparasitic and antibiotic drugs.

The issue of domestic complex chemotherapeutic drugs or medicines containing in its structure a means of plant origin for the prevention of endometritis in cows, is limited, especially ready-made forms for intrauterine use, such as suppositories, sticks, tablets, etc. that creates a lot of problems in practice.

Well-known medication for the treatment of postpartum endometritis in cows "Furope" - furazolidone sticks, which are used intrauterinely. Their efficiency is very low, because the drug is present only furazolidone, which does not fully resolve present in the uterus of cows microflora, resulting in endometritis take a chronic form [1, 2] .

Also known drugs for intrauterine use suppository "Gelmicin" and suppository "Ekziter" [3]. Both drugs produced abroad (Hungary, Croatia). Effective domestic preparations for intrauterine use in veterinary medicine in the form of suppositories no.

The technical result is bactericidal effect, increasing the activity of regenerative processes in pathological tissues of the uterus, restoring reproductive) suppository "Glycerite contains thelan (tylosin), furazolidone, licorice root extract, tansy and glycerin in the following ratio of initial components, wt.%:

thelan - 7,0 - 7,5

norsulfazol - 7,0 - 7,5

furazolidone - 7,0 - 7,5

licorice root (Radix Glycyrrizac) - 39,0 - 40,0

extract of tansy (Herba Tanaceti) - 33,0 - 35,0

glycerin - rest

Activetestsuite substances are crushed, the settlement amount is weighed, mixed, add the calculated amount of glycerin, carefully mix a lot until smooth. Suppositories made known methods so that the weight of one suppository was 9-10 g, and dried in the open air to constant weight. Each suppository contains:

thelan - 0,5 - 0,8

norsulfazol - 0,5 - 0,8

furazolidone - 0,5 - 0,8

licorice root - 4,0 - 4,5

extract of tansy - 1,0 - 1,5

glycerin - 3,5 - 4,0

In the proposed suppositories "Glycerite" the complex of active substances are selected in such a way that the combination of components in the specified ratio provides maximum bactericidal and anti-inflammatory effect. Licorice root extract of tansy contains a set of biologically active substances - glycerin, glucose, saponins, protein, tannins, mucous is ncciu.

In examples 1, 2, 3 lists the specific formulations of the drug, wt.%:

Example 1.

thelan - 7,0

norsulfazol - 7,0

furazolidone - 7,0

licorice root - 39,0

extract of tansy 33,0

glycerin - rest

Example 2.

thelan - 7,2

norsulfazol - 7,2

furazolidone - 7,2

licorice root - 39,5

extract of tansy 340

glycerin - rest

Example 3.

thelan - 7,5

norsulfazol - 7,5

furazolidone - 7,5

licorice root - 40,0

extract of tansy 35,0

glycerin - rest

The use of the drug in amounts greater than the above limits, is not economically feasible, and in quantity is less than the specified limits, the effectiveness of the drug is reduced.

The product of example 1 in the amount of 1 kg is prepared as follows.

Powdered ingredients sifted through a sieve with a mesh size of 0.25 mm is Weighed 70 grams of thelan, norsulfazola, furazolidone, 390 g of licorice root, in a porcelain Cup mix until smooth, then add 70 g of glycerol and 330 g of the extract of tansy, mix until uniform weight and the resulting mass is formed into suppositories by 10 grams, drying with up to constant weight.

PIM smell. Keeps the stability in a cool dark place for 12 months.

therapeutic efficacy of the proposed drug was tested in comparison with a known drug intrauterine sticks with Furazolidone".

The test was carried out on cows with acute postpartum and purulent endometritis, and after surgical Department, to the rear of the placenta. After surgical separation of placenta inside the uterus used 1 suppository in the treatment of acute postpartum endometritis 1 suppository 2-3 times with an interval of 24 hours, and purulent endometritis - 1-2 suppository 4-5 times with an interval of 24 hours.

It is established that the use of suppositories group of cows (n = 88) after surgical separation of placenta was not observed in the occurrence of postpartum endometritis. When treating cows (n = 86) with acute postpartum and purulent (n = 47) endometritis treatment effect was 89,0 and 83.5%, respectively, whereas in the control group, where the treatment was applied the well-known drug (base case) the efficiency was 42% and 45%, respectively.

Well-known drug and intrauterine sticks with Furazolidonum" was introduced in 4-6 pieces Therapeutic efficacy predlozennogo preventive and curative action, harmless, has antiseptic and anti-inflammatory activity, is not addictive to him microorganisms.

Sources of information

1. The Polyantsev N. I., Sinyavin A. N. Obstetric-gynecological examination on dairy farms. M: Rosagropromizdat, 1989, S. 134-154.

2. Bezborodov centuries Bacterial contamination of the uterus of cows and its effect on the reproductive function after childbirth. Abstract of Cand. Diss., M., 1982, S. 8-24.

3. Karotkin, C., B. Timofeev A., Sozinov C. A. Handbook of veterinary drugs (chemotherapy drugs). Kirov, 1997, S. 364, 577.

A drug for prevention and treatment of postpartum endometritis in cows containing activetestsuite and excipients, characterized in that the quality of active substances contains thelan, norsulfazol, furazolidone, licorice root extract, tansy, and as excipients glycerol under the following ratios of all the original components, wt. %:

Thelan - 7,0 - 7,5

Norsulfazol - 7,0 - 7,5

Furazolidone - 7,0 - 7,5

Licorice root - 39,0 - 40,0

Extract of tansy - 33,0 - 35,0

Glycerin - Rest

 

Same patents:

The invention relates to veterinary medicine, in particular drugs for the treatment of mastitis in cattle
The invention relates to medicine, in particular to obstetrics, and for measures aimed at improving the reproductive health of the population
The invention relates to medicine, in particular for secondary prevention post-radiation impaired spermatogenesis, and can be used in medical and health institutions
The invention relates to the field of medicine

The invention relates to new naphtylpropionate F.-ly (I), where R1and R2- N, -HE or-O(C1-C4-alkyl); R3- 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholinyl, dialkylamino - or 1-hexamethylen-aminogroup; n = 2 or 3, or pharmaceutically acceptable salts

The invention relates to medicine, namely to andrology, reproductive science

The invention relates to new niftystories compounds of formula I, where R1and R2- H, -OH, -O(C1-C4alkyl), -OCOC6H5, -OCO(C1-C6alkyl), -OSO2(C4-C6alkyl); R3- 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, 1 hexamethyleneimino; intermediate compounds, which are suitable for easing symptoms of postmenopausal syndrome, including osteoporosis, hyperlipemia and estrogenzawisimy cancer, and inhibition of uterine fibroids, endometriosis and proliferation of aortic smooth muscle cells

The invention relates to the field of medicine and relates to a pharmaceutical combination preparation for hormonal contraception

The invention relates to the field of medicine and relates to a pharmaceutical combination preparation of the two, Packed in spatial terms separately in the same packaging unit, intended for oral administration at a time sequentially hormonal components, which consist, depending on the circumstances, placed in spatial terms separately in one packing unit and retrieved separately daily dosing units, and the first hormonal component as hormonal biologically active substance contains a combination of estrogen and at least sufficient to suppress ovulation dosage gestagenna the drug either in-phase or multi-phase execution, and the second hormonal component as hormonal biologically active substance contains only one estrogen drug, and the first hormonal component covers 23 or 25, and the second hormonal component covers 4-10 daily dosing units, daily dosage units of the first hormonal component does not contain a combination of biogenic estrogen and synthetic estrogen, and the total number of daily dosing

The invention relates to veterinary medicine, in particular drugs for the treatment of mastitis in cattle

The invention relates to new substituted 1,2,3,4-tetrahydro-2-naphthalenamine formula I, where R1and R2independently represent hydrogen, C1-4alkyl, C1-4alkoxy, halogen, trifluoromethyl; R3represents hydrogen, hydroxyl, C1-4alkoxyl, cyano, carbarnoyl; R4and R5independently represent hydrogen, C1-4alkyl, hydroxy2-4alkyl, or form together with the nitrogen atom to which they are attached, piperidine; in the form of free bases or salts obtained by attaching acid

The invention relates to new substituted 1,2,3,4-tetrahydro-2-naphthalenamine formula I, where R1and R2independently represent hydrogen, C1-4alkyl, C1-4alkoxy, halogen, trifluoromethyl; R3represents hydrogen, hydroxyl, C1-4alkoxyl, cyano, carbarnoyl; R4and R5independently represent hydrogen, C1-4alkyl, hydroxy2-4alkyl, or form together with the nitrogen atom to which they are attached, piperidine; in the form of free bases or salts obtained by attaching acid
The invention relates to medicine, in particular to obstetrics, and for measures aimed at improving the reproductive health of the population

The invention relates to medicine, namely to surgery
The invention relates to the field of pharmacology, and relates to means for correcting energy metabolism
The invention relates to the field of medicine

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

Up!